EUVIMEDEUVIMED entdecken
Crossref

Cationic Lipid Stearylamine Displays Fast‐Acting Antimalarial Action Against In Vitro Blood Stages of Chloroquine Susceptible and Resistant Plasmodium falciparum Strains

Vinoth Rajendran iD, Keerthana Gurukkalot iD, Nimitha Cherthedath Naveen iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Vinoth Rajendran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Life Sciences, Pondicherry University, Puducherry, India. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Chloroquine, Amines. Die Arbeit nennt 44 Literaturangaben. Gefördert von: The V.R. lab is supported by a research grant from the Department of Science & Technology (DST), INSPIRE-Faculty Project (DST/INSPIRE/04/2018/003541), Ministry….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The growing resistance of malarial parasites to antiplasmodial drugs has necessitated the development of a new class of potent molecules to reduce the global malaria burden. This study evaluated the antimalarial efficacy of the cationic lipid stearylamine (SA) on blood‐stage Plasmodium falciparum using SYBR‐Green I assay. We conducted in vitro studies to assess the timing of SA action in drug‐sensitive ( Pf 3D7) and chloroquine‐resistant ( Pf INDO) strains of P. falciparum . Notably, SA demonstrated fast‐acting cytostatic potential with 50% inhibitory concentration (IC 50 s) values of 2.17, 1.97, and 1.33 µg/mL for Pf 3D7 and 3.50, 2.76, and 1.94 µg/mL for Pf INDO during the first generation cycle (12, 24, and 48 h), and the activity was maintained during the second generation cycle with IC 50 values at 72 h (1.15 µg/mL on Pf 3D7 and 1.65 µg/mL on Pf INDO) and 96 h (1.43 µg/mL on Pf 3D7 and 1.10 µg/mL on Pf INDO). Additionally, we explored the cytocidal potential of SA by exposing the parasites for 1, 2, 4, and 6 h and subsequent incubation for 48 h in SA‐free conditions, which revealed an average IC 50 value of 1.68 µg/mL, demonstrating its irreversible parasite growth arrest. Moreover, SA induced reactive oxygen species (ROS) production at IC 50 concentrations, with minimal hemolytic effects. Our findings indicated that incorporating SA into lipid vehicles or other delivery systems loaded with antimalarial drugs can significantly reduce drug toxicity, enhance efficacy, and slow clinical resistance. Nevertheless, further preclinical studies are warranted to advance the antimalarial drug discovery pipeline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumChloroquineAminesDrug ResistanceHumansInhibitory Concentration 50Parasitic Sensitivity Tests

Stichwörter der Autor:innen

P. falciparumblood‐stagecytocidalstearylaminetiming of action

Substanzen

AntimalarialsChloroquinestearylamineAmines

Autor:innen und Institutionen

  • Department of Microbiology, School of Life Sciences, Pondicherry University, Puducherry, India.

ORCID-Profile: Vinoth Rajendran, Keerthana Gurukkalot, Nimitha Cherthedath Naveen

Förderung

  • The V.R. lab is supported by a research grant from the Department of Science & Technology (DST), INSPIRE-Faculty Project (DST/INSPIRE/04/2018/003541), Ministry…

Zitieren

APA

Rajendran, V., Gurukkalot, K., & Naveen, N. C. (2025). Cationic Lipid Stearylamine Displays Fast‐Acting Antimalarial Action Against In Vitro Blood Stages of Chloroquine Susceptible and Resistant Plasmodium falciparum Strains. Drug Development Research. https://doi.org/10.1002/ddr.70147

Vancouver

Rajendran V, Gurukkalot K, Naveen NC. Cationic Lipid Stearylamine Displays Fast‐Acting Antimalarial Action Against In Vitro Blood Stages of Chloroquine Susceptible and Resistant Plasmodium falciparum Strains. Drug Development Research. 2025. doi:10.1002/ddr.70147

BibTeX
@article{Rajendran2025,
  author = {Rajendran, Vinoth and Gurukkalot, Keerthana and Naveen, Nimitha Cherthedath},
  title = {Cationic Lipid Stearylamine Displays Fast‐Acting Antimalarial Action Against In Vitro Blood Stages of Chloroquine Susceptible and Resistant Plasmodium falciparum Strains},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70147}
}
Kostenlos starten →